A R&D based

Global Biopharmaceutical Company

April. 2017
Disclaimer
The IR information on this document is provided for the purpose of outlining Medytox's financial
information, management objectives, and other information of a similar nature. No guarantee is
made in relation to the contents. The information presented on this material is not for the purpose
of soliciting potential investors. Investors should exercise their own independent judgment when
making any investment decision, and should avoid depending solely on the information presented
on the document.

All financial information contained in this document is based on consolidated K-IFRS. This
document may contain information and financial data that have not been audited by an
independent auditor. The reason for our earnings release announcement prior to an independent
auditor’s audit is to communicate our financial results to the market and investors in a timely
manner. Therefore, the information and financial data contained in this document are subject to
change upon an independent auditor’s audit.

The company does not make any representation or warranty, as to the accuracy or completeness
of the information contained in this document. And we are not responsible for the update on
content that described current facts
Table of Contents

1 Company Overview

2 R&D Capability and Plant

3 Product Lineup

4 Globalization
Company Overview

A R&D Based Global Frontier of Korea Value Creation

Biopharmaceutical Bio Pharmaceutical for Happy &
Company Industry Healthy life

 Successfully developed  The frontier of Korea  Commitment to

the fourth Botulinum biopharmaceutical providing the best
toxin type A product in Industry thanks to products through
the world and Hyaluronic top-tier Biotechnologists, best technology and
acid filler and to its state-of-the manpower
 Advancing to more than -art operations and  Continuing extensive
60 countries production facilities R&D Investment to
evolve into a true
global biotech leader

4
Company Overview
Core Competitiveness of Company
Best Products
Best Products
• Classification: Biologics
• First liquid type botulinum
toxin A product
• License agreement with
Allergan for the Next
Generation Botulinum Toxin
Core Competitiveness
Best R&D and
Manufacturing Technology
• BL3 (Bio Safety Level 3) facility
and equipment needed for
production of toxin-based
medicine
• The only company that
developed both toxins and
fillers internally in the world
• Professionals experienced with
botulinum toxin development
are limited in numbers.
Differentiation
from competitors
Authentic Botulinum
Toxin Strains
• Clostridium Botulinum toxin:
limited for development,
production, possession, and
delivery
• ATCC(a global bio resource
center) prohibited distribution of
Clostridium botulinum
5
Company Overview Fact Sheet & Locations

Fact Sheet
Establishment 2 May 2000
Capital USD 2.6 million (2016)
Market
USD 2.4 billions (2017.04)
Capital
Headcount 467 Employees (2017.03)
Revenue USD 111 millions (2016)

Territory Offices
Ochang (Headquarter / Plant I /
R&D Center)
Osong (Plant II, Plant Ⅲ),
Domestic
Seoul(Office)
Medytox Korea (Seoul, Busan,
Daegu, Gwangju, Daejeon)
Pangyo, Gwanggyo(R&D Center)
Medytox US (Maryland)
MDT International (Tokyo)
Overseas Medytox Taiwan*JV
Medybloom China *JV
MedyCeles (*JV in Thailand)
Medytox Hong Kong *JV

6
Company Overview Company History

2011
• Selected as an Advanced 2015
Technology Center(ATC) by • Established Medybloom
Ministry of Knowledge China and Medytox
2002 Economy Taiwan (Joint Venture)
• Completed Ochang • Obtained KGMP Approval • Established MDT
PlantⅠ (KGMP) for Neuramis® in Ochang International(Tokyo)
Construction PlantⅠ • Obtained Marketing
• Received $10M Export
2006 2008 Tower Award from the
Approval from *MFDS for
Neuramis® Series
• Obtained Marketing • Selected as Bio Star Ministry of Knowledge • Obtained Marketing
2000 Approval from KFDA for Enterprise’ by the Economy Approval from MFDS* for
• Established Neuronox® Ministry of • Received CE marking INNOTOX® 50U
Medytox Inc. • Selected as ‘World-class Knowledge Economy (Conformité Européenne) • Groundbreaking of
product’ for Neuronox® by for Neuramis® Deep Medytox Plant Ⅲ
the Ministry of Industry
and Resources

*MFDS: Former KFDA

2001 2007 2009 2012 2016

• Established the • Opened Medytox Inc. • Listed on KOSDAQ • Groundbreaking of Osong • Obtained KGMP Approval
Microbial Toxin Seoul office • Obtained Marketing Plant II (cGMP / EU GMP) for Medytox Plant Ⅲ
R&D Center Approval from KFDA for • Obtained Marketing
Neuronox® 200U 2014 Approval in Russia for
• Received $5M Export • Received the Grand Prize Neuramis® Series
Tower Award from the at the 6th Korea • Obtained Marketing
2004 Ministry of Knowledge Technology Award from Approval in Mexico for
• Obtained KGMP Approval Economy the Ministry of Trade, Neuronox® 50, 100, 200U
for Ochang Plant Ⅰ, the • Achieved No.1 Market Industry and Energy • Obtained marketing
Delicated Facility for Share in the Botulinum • Obtained Marketing Approval from MFDS
Neuronox® Toxin Market in Korea Approval from *MFDS for for Coretox® 100U
Neuramis® Deep Lidocaine
7
 Company Overview Recent Performances

Recent 5 Years Results Business Highlights

Sales Operating Income ’16 Highlights

(Unit: 100mn KRW)  Obtained marketing approval from MFDS
1400 1333
for Coretox® 100U
1200

1000 885  Obtained marketing approval in Mexico for

759
800 752 Neuronox® 50U, 100U, 200U

600 500 517  Obtained marketing approval for

363 391
400 Neuramis® Series in Russia
168
200 170
 Received KGMP approval for Medytox
0
Plant Ⅲ(Osong) and export product
2012 2013 2014 2015 2016
approval for Neuronox® 100U
Operating
Income
47% 43% 66% 58% 56%  The first year that sales exceed KRW
100bn

8
Table of Contents

1 Company Overview

2 R&D Capability and Plant

3 Product Lineup

4 Globalization
R&D Capability

Superior Competitiveness of Medytox’ biotechnology

Core Capabilities Product Development

1) State of the art R&D capability and
1) Development of the first botulinum
infrastructure
toxin biopharmaceutical in Korea, and
2) Participation in various government-led the fourth in the world
R&D projects (Non animal source & No HSA)

3) World-class botulinum toxin R&D team 2) Development of a compatible hyaluronic

acid filler
4) Expansion of R&D area to cover the
development of various medical aesthetic 3) Development of new medical aesthetic
products products

5) Continuous R&D investment for the

development of new biopharmaceutical 4) Development of innovative biologics
products

10
Gwanggyo R&D Center
 A R&D center for research and development on new biopharmaceutical products will be
completed in 2017

Core Capabilities Design of Gwanggyo R&D Center

Protein engineering

Antibody engineering

Cell biology

Anti-aging Science

And More

11
 Medytox Plant I(Ochang)

Location: Ochang Bio Industrial Complex(size : 4851㎥)

Nov. 2004 Mar. 2007 May. 2008 July. 2010 Dec. 2011 Mar. 2013 Oct. 2013 Apr. 2015
Approval of KGMP Inspection from Inspection from Inspection from Approval of CE certificate for ISO13485 & CE Inspection from ISO13485 &
for biologics and MOH of Saudi INVIMA of KFDA Neuramis® Deep from EVPU, surveillance audit SAUNP of CE(1293)
injectable Arabia Colombia Inspection from KFDA from EVPU Ukraine Renewal
inspection

Jul. 2013 Mar. 2014

Jun. 2002 Mar. 2006 Jul. 2007 Oct. 2008 Feb. 2011 Feb. 2012 Approval of
Completion of Approval of Construction of Inspection from Approval of Audit form Inspection from
INVIMA of Neuramis® Deep
manufacturing Marketing R&D center and ANVISA of Brazil ISO13485 Bergamo &
Colombia Lidocaine from MFDS
facility set-up Authority for animal facility Certificate from Amgen of Brazil
Meditoxin® EVPU ISO13485
surveillance
audit from EVPU Microbial Toxin R&D Center
Production Line for Botulinum Toxin Injectable
Production Line for HA Dermal Filler
Animal Facility

Packaging/ Cafeteria

12
 Medytox Plant II(Osong)
 A New facility based on EU/cGMP standards enables Medytox to penetrate in US and
European countries

Features of Plant Current Progress

 Location : Bio Industrial Park(17,820㎡)  Present ~ : Under Validation

 May. 2014 : Completed Construction
 Expected Capacity : Approx. KRW 600 billion
 May. 2012 : Started Construction
 CAPEX : Approx. US$ 32 million

Production Line for Botulinum Toxin Injectable

& R&D Center

13
 Medytox Plant Ⅲ(Osong)
 The facility for botulinum toxin was completed and obtained KGMP approval. The facility for
HA filler is being constructed for global expansion

Features of Plant Design of Plant

 Location : Osong(5min away from plant Ⅱ)

 CAPEX : Approx. KRW 55.6billion

 Period : 2015~2018(4 years)

 Area Size : Land 14,725㎡

Building floor area 15,328㎡

14
License-out Contract to Allergan
 Medytox in Sep 2013 licensed its next-generation botulinum toxin product to Allergan,
with one of the largest-ever milestone payments for a Korean pharmaceutical player.

1) Upfront fee: $65m

(received in Jan 2014)

Milestone Total 2) Development milestone :

$362m $116.5m
($15m was received in Aug 2014)
3) Sales milestone : $180.5m

Royalty based on
Royalty
Sales

Products will be
Product
manufactured by
Sales Medytox

15
Table of Contents

1 Company Overview

2 R&D Capability and Plant

3 Product Lineup

4 Globalization
Product Lineup Neuronox®
 Neuronox® is a representative botulinum toxin type A product of Medytox that is being
exported to about 60 countries. Neuronox® ranks No.1 in market share in Korea and has
gained significant market share in many countries.

Korea’s First & The Fourth In The World Sale of over 6 million Vials

 Proven Efficacy & Safety

– Proved efficacy and safety in clinical studies,
with results published in distinguished academic
Journal such as Dermatologic Surgery.

 Global Product
– Global Product, Neuronox® has been sold in
over 60 countries, since its first launch in 2004.
Neuronox® is being sold worldwide (Registered
in 29 countries, Registration in progress in 30
additional countries)

 Various Choices
– Neuronox® line up is consisted of 50, 100, 150
and 200 units, offering various choices according
to the application. Physicians find it easier to use
and the patients more economical.
17
Product Lineup INNOTOX®
 INNOTOX® is the world’s first liquid formulation of botulinum toxin type A product,
developed and launched in 2014. INNOTOX® is an innovative excluding animal-derived
ingredients and human serum albumin
 Currently INNOTOX® is being sold in Korea and it is emerging as the product to show our
distinguished R&D capabilities.

First Liquid Formulation in the World Enhanced Safety

 The world’s first liquid formulation of botulinum

toxin type A
– Exclusive of animal source and Human
Serum Albumin

 User friendly
– Enhanced user’s convenience without dilution
process, which minimizes potential hygiene
problems

 Proven Efficacy & Safety

– Proved efficacy and safety in clinical study

 Accurate Dose
– Exact dose for injection
(INNOTOX® 0.1mL = 4unit)

18
Product Lineup Coretox®
 Coretox® is an advanced new botulinum toxin type A product that excludes animal
derivatives, HSA and non-toxin proteins from its ingredients. It prevents the immune
system from developing antibodies that would eventually wear down the effects of
botulinum toxin type A

The New Choice of Heavy and Regular Users

 Medytox has obtained Coretox® marketing approval in 2016, which was developed as the 3rd
botulinum toxin type A product. Coretox ® will be launched in Korea market in the second half

of 2017

19
Product Lineup Neuramis®
 Neuramis® is the premium hyaluronic acid dermal filler product developed and launched in
2013. Neuramis® Deep attained CE mark in 2011 and We have also secured our position in
dermal filler market by obtaining the marketing authorization of Neuramis® series, a
hyaluronic acid filler containing lidocaine

The New Choice of Hyaluronic Acid Dermal Filler

 Enhanced Satety  High Satisfaction

– Enhanced safety by using high quality
hyaluronic acid registered in FDA and EDQM as
raw material and through enhanced purification
process and final sterilization process
 Long Lasting Efficacy
– Enhanced durability of effect by performing
crosslinking twice
– High customer satisfaction by providing natural
looking volume after administration.
 Easy to Use
– Ideal properties developed scientifically, giving
rise to even extrusion force
– Even and uniform injection to minimize pain and
enhance convenience of administration

Rapidly Growing Sales

(Unit: 100mn KRW) Neuramis® Sales
187
180
135 140
150
120 100 140
81
90 64
60 50
25 31
30 6 6 8 12
0
13 13 14 14 14 14 15 15 15 15 16 16 16 16
3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 20
Table of Contents

1 Company Overview

2 R&D Capability and Plant

3 Product Lineup

4 Globalization
 Globalization Domestic Market

 Since 2006, the domestic botulinum toxin market has been grown constantly(CAGR:10%)
 After Neuronox®’s 2006 launch, the market share has expanded from 8% to 40%

Domestic Market Size Domestic Market Share

Unit : KRW100mn
800 45%
726 740 40% 40%
703 40% 38%
700 660
630 36% 39%
605 35%
556 35%
600 34% 35%
30%

500 456 25%

406 25%
400 20%
317 18%
15%
300
10%
200 8%
5% Meditoxin®
100 0% Launching
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 (Source: Medytox, corporate disclosure)

22
 Globalization Global Market

 In 2015, US & EU made up 75% of the world botulinum toxin market

(US market : 51%, EU market : 24%, Global market CAGR: 12.3%)

Global Market Size Global Market Status Global Market Share

Botox(US) Dysport(France)
Unit : $millions USA EU ROW Xeomin(Germany) BTX-A(China)
3,380
3,500 3,213 Meditoxin(Korea)

2,822
3,000 2.5%
2,493 5.4%
2,500 2,202 24.1%
1,844 14.7%
2,000 1,688

1,500 2015 51.2% 2015

1,000
24.7%
500 75.9%

-
2009 2010 2011 2012 2013 2014 2015

(Source : UBS Pharmaceutical Handbook, Jun, 2016)

23
 Globalization Global Market Forecast

 Botulinum toxin market is expected to grow from $3.6bn to $5.6bn by 2020

(US market 50.9%, ROW* 25.0% → 26.2%, EU 24.1% → 22.9%)

Global Market Segmentation Global Market Portion

USA EU ROW

Unit : $millions Aesthetic Therapeutic

24.1%
6,000
5,062 2015 51.2% $3.38bn
4,648
5,000
4,237
3,861 24.7%
4,000 3,380 3,561 59%
3,213 58%
57%
2,822 57%
3,000 2,493 57%
2,202 59%
56%
54%
2,000 53%
53%
42 41
43 43
41 43 % %
1,000 47 46 44 % %
47 % %
% % %
% 23.3%
-
2011 2012 2013 2014 2015 2016E 2017E 2018E 2019E 2020E

(Source : UBS Pharmaceutical Handbook, Jun, 2016)

2020E 56.2% $5.06bn
*ROW: Rest Of World
20.4%

24
 Globalization Global Network
Registered in 34 countries

ASIA AMERICA
AZERBAIJAN GEORGIA HONG KONG INDIA IRAN BOLIVIA BRAZIL CHILE COLUMBIA COSTARICA
KAZAKHSTAN KOREA KYRGYZSTAN LEBANON DOMINICA REP EQUADOR EL SALVADOR GUATEMALA
MYANMAR MONGOLIA PHILIPPINES SYRIA THAILAND MEXICO NICARAGUA PANAMA PRAGUAY PERU
UZBEKISTAN VIETNNAM

EUROPE
UKRAINE ESTONIA SPAIN BELARUS
25
* Red : Neuronox® & Neuramis® , Black: Neuronox® , Blue: Neuramis®
Globalization Global Strategy
 Successful direct penetration in EM markets and experience from partnership with
Allergan will enable Medytox to go actively to developed markets

Penetration
in developed Long Term
markets
Medybloom China MedyCeles(Thailand)
(Jul. 2015) (Mar. 2017)
 Developed market
penetration with
Direct
penetration Mid Term Neuronox® and
in Asia Neuramis® through
Medytox Taiwan license out or JV
(Feb. 2015)
 Global launch
of liquid formulation
Number one
Present product through
in Korea and
EM markets Allergan
 Direct penetration in
 Emerging market China and Taiwan
penetration through markets through
local distributorship JV with Neuronox®
and Neuramis®

26
Globalization Global Strategy

Present Mid term Long term

Neuronox® is selling Direct penetration

Penetration in
Neuronox® over 60 countries In Asia markets
EU and US markets
through local agents through JV

Liquid solution  Launched INNOTOX® Marketing approval

of botulinum 25U in Korea(Jun, 2014) and launch by Capturing significant
toxin A  Launch INNOTOX® 50U Allergan in EU and market share
(INNOTOX® ) in Korea(Jun, 2015) US markets

 Clinical study finished

in Korea. Launch Coretox® Penetration in
Coretox®  Obtain marketing in overseas markets EU and US markets
approval Q2 in 2016

 Rapidly growing sales

in EM market
Neuramis®  Neuramis® series Penetration in EU Penetration in US
Series containing lidocaine market market
obtained approval in
Korea(March, 2015)

27
Global Research-based Biopharmaceutical Company